Development of a validated HPLC method for determination of an active component in Pycnocycla spinosa and tablets prepared from its extract by Tavakolli, Naser. et al.
Journal of Herbmed Pharmacology
Journal homepage: http://www.herbmedpharmacol.com                
J Herbmed Pharmacol. 2017; 6(1): 37-42.
Development of a validated HPLC method for determination 
of an active component in Pycnocycla spinosa and tablets 
prepared from its extract
Naser Tavakolli1, Mustafa Ghanadian2,3*, Gholamreza Asghari3, Hassan Sadraei4, Nadia Asgari Borjlou1, Majid 
Tabakhian1
1Department of Pharmaceutics, school of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran  
2Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3Department of Pharmacognosy, school of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran 
4Department of Pharmacology, school of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
*Corresponding author: Mustafa Ghanadian, Tel: +98-3137927131; 
Email: ghannadian@gmail.com
Introduction
Diarrhea is a common disease of tropical areas responsible 
for mortality of children and infants. Irritable bowel 
syndrome (IBS) is another digestive tract disease 
associated with intestinal movement problems. Anti-
motility drugs such as loperamide and anti-muscarinic 
agents like dicyclomine may relieve diarrhea and reduce 
intestinal spasm and the pain (1,2). Alverine, mebeverine 
and peppermint oil are between other antispasmodic 
agents believed to be direct relaxant of intestinal smooth 
muscle and may alleviate the pain in IBS and diverticular 
diseases (3).
Pycnocycla spinosa (Umbelliferae family), a native plant 
growing wild in Iran (4) has showed also considerable 
antispasmodic and antidiarrheal activities in mice 
comparable with loperamide (5-7) and could be a 
suitable candidate and an alternative remedy for the 
treatment of diarrhea and IBS. Using chromatography 
separation techniques, potent fractions have been 
separated from its crude extract and further researches 
led to the identification of its bioactive compounds 
including 3,7,10,14,15-pentaacetyl-5-butanoyl-13,17-
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Introduction: Pycnocycla spinosa, a native plant of Iran with approved antispasmodic and 
antidiarrheal activities, could be a suitable candidate and an alternative remedy for the treatment 
of diarrhea and irritable bowel syndrome (IBS). Therefore, the aim of this study is formulation of an 
acceptable dosage form and development of a validated high-performance liquid chromatography 
(HPLC) method for analysis of active ingredients in its extract and pharmaceutical forms. 
Methods: Different formulations of P. spinosa tablets were prepared by wet granulation method. 
The prepared tablets were evaluated for hardness, friability, disintegration time and drug assay. 
HPLC was carried out based on the extract active ingredient: 6-(4-hydroxy-3-methoxyphenyl)-
hexanoic acid (HMPHA) determination in P. spinosa extract and tablets. 
Results: The mean weight, friability, hardness, and disintegration time of selected formulation 
(tablet 5 mg) were 217.26 mg, 0.69%, 53.6 N and 95.8 seconds, respectively. Similar acceptable 
results were also found for 10 mg tablets. The assay test showed that the content of HMPHA in 
each 5 mg and 10 mg tablets were 1.64 μg and 3.59 μg, respectively. The HPLC method showed a 
good linearity and suitability in its working range: 4.5 to 15 µg/mL. 
Conclusion: The data showed that the selected formulation of P. spinosa tablets has acceptable 
physicochemical features. 
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epoxy-8-myrsinene (PABEM), vanillin, isoacetovanilon 
(isoapocynine), and 6-(4-hydroxy-3- methoxyphenyl)-
hexanoic acid (HMPHA) (8). HMPHA as depicted in figure 
1 is a phenyl hexanoid structure which has significantly 
reduced ileum contraction induced by acetylcholine, 
serotonine and electrical field stimulation in vitro in a 
concentration-dependent manner on isolated rat ileum 
(9). It strongly inhibited gut movements and reduced 
diarrhea induced by castor oil or sulphate magnesium 
in rats (9). With regard to mentioned biochemical and 
pharmacological researches which have done on P. spinosa 
extract (3-9), an acceptable formulation and a reliable high-
performance liquid chromatography (HPLC) method for 
analysis of active ingredients in its pharmaceutical forms 
is required. To the best of our knowledge, no studies on 
the quantitative determination of chemical constituents 
in P. spinosa are reported. Therefore, HMPHA as one of 
the major and bioactive components with high molar 
UV absorption required for spectrophotometer analysis 
was selected to be quantified and applied as an important 
index in the quantity evaluation of the bulk drug or 
pharmaceutical formulations of P. spinosa. In this study a 
was established as a validated, simple, rapid and accurate 
method for HMPHA determination in the bulk extract of 
P. spinosa and a tablet dosage form of the plant. 
Materials and Methods
Chemicals
Methanol, chloroform, acetone, and hexane were 
of analytical grade prepared from Merck Company 
(Germany). Hexane and chloroform HPLC-grade solvents 
were purchased from Caledon Company (Canada). 
Cerium ammonium molibydate (CAM) TLC reagent was 
prepared by adding 0.5 g of ceric ammonium molybdate, 
12 g of ammonium molybdate, and 15 mL of sulfuric acid 
to 235 mL of distilled water in a 250 mL Erlenmeyer flask 
(10). HMPHA (Figure 1) was isolated form P. spinosa 
extract as described before (8). 
Preparation of the Extract
The aerial parts of P. spinosa were collected at October 
from populations grow wild in Isfahan University of 
Isfahan, Isfahan, Iran. The plant was identified according 
to the voucher specimen A24 deposited at the herbarium 
of the Faculty of Pharmacy of Isfahan University of 
Medical Sciences, Iran. Aerial parts of plant material (400 
g) were air-dried in the shade and reduced to fine particles 
using an electric mill. The powdered plant was extracted 
exhaustively via percolation using ethanol: water (70:30) 
as solvent at a flow rate of 200 μL/min for 24 hours. The 
extract was concentrated under reduced pressure by a 
rotary evaporator at 40°C to yield 55.5 g gummy extract. 
HPLC method for determination of HMPHA
HMPHA was determined through external standard 
calibration method on a Waters system, equipped with 515 
HPLC pump, 2487 dual wavelength absorbance detector 
(Waters, Milford, MA, USA). The column was a Nova-
Pak Silica, 3.9 × 150 mm (Waters, Milford, MA, USA) and 
Millennium software was used for the determination of 
compounds and processing the data. 
Base on the knowledge of HMPHA different HPLC 
methods including reverse phase methods at the initial 
stage and normal phase chromatographic methods as the 
second choice were tested. 
Preparation of the Standard Solutions 
For preparation of the standard solutions, 1000 μg of pure 
HMPHA powder was diluted in 1 mL of HPLC mobile 
phase solvent to prepare the stock solution of 1000 μg/mL. 
Different standard solutions at concentrations of 4.5, 6, 8, 
10, 12.5, and 15 μg/mL were prepared by serially diluting 
the stock solution. 
Solvent effect 
For evaluation of the solvent effects as one of the affecting 
parameters on the extraction of the HMPHA from extracts 
and tablets, chloroform, acetone, and methanol solvents 
with different strength and selectivity’s were selected. 
Then, two extraction methods consisted of maceration 
(24 hours) in combination with ultrasonic radiation (120 
minutes) or ultra-sonication alone were compared to 
check the effect of the procedure on the extraction (12). 
Selectivity
The ability of the HPLC method to separate all closely 
eluted compounds and excipients from HMPHA band 
was calculated by assessing resolution (Rs) and separation 
factor (α). The tailing factor and column efficiency for 
HMPHA was also assessed. Column resolution (Rs) and 
separation factor (α) were calculated by using equation, 
Rs=2(Rta-Rtb)/(WA+Wb), and (α) = (Rtb – tm)/(Rta –
tm), where Rta, Rtb are retention times and Wa, Wb are 
band width of peak A and B in chromatogram. For a 
precise and rugged HPLC analysis resolution of 1.5 and 
symmetry factor less than 1.5 are required (11,14). 
Limit of detection and limit of quantification 
Limit of detection (LOD) or the minimum amount of 
analyte which can be detected reliably is a peak which 
its signal-to-noise ratio is at least 3:1. The limit of 
quantification (LOQ) or minimum quantifiable amount 
is the concentration which can be quantified with a 
 
Figure 1. Structure of 6-(4-hydroxy-3-methoxyphenyl)-hexanoic 
acid (HMPHA) isolated from Pycnocycla spinosa.
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specified level of accuracy and is often calculated with a 
similar method for LOD whose signal-to-noise ratio is at 
least 10:1. But in this study LOQ was defined with Relative 
standard deviation (RSD) less than 3, experimentally, by 
injecting different concentrations of standard with signal-
to-noise ratios of 10, 15, 20, and 25 (13-15). 
 
Linearity and range 
The linearity means how well a calibration plot of response 
versus concentration approximates a straight line. It was 
done by linear squares regression. Correlation coefficient 
(r2) in addition to plot slop and intercept provided desired 
information on linearity. In HPLC validation methods, 
a linearity correlation coefficient more than 0.999 is 
acceptable (14). 
Linear range starts from the LOQ of the component of 
interest as the lower concentration and extend up to its 
upper concentrations in which the HPLC method have 
acceptable linearity, accuracy and precision. Therefore, 
working range in this study was selected within the linear 
range beyond values expected in the sample at 50, 70, 100, 
125, and 150% of HMPHA in 30 mg extract (4.5, 6, 8, 10, 
12.5, and 15 μg/mL) (14). 
 
Precision 
Precision is the degree of agreement among individual 
test results. Therefore, precision could be evaluated when 
a series of concentrations of the same analyte is done 
repeatedly through repeatability assays like intra-day 
precision, and intermediate precision assays like inter-day 
precision. RSD was calculated by using the equation % 
RSD = (SD/X) * 100, where SD is the standard deviation 
which is calculated for each level of precision, and X is the 
mean of responses. When there is an unacceptable RSD, its 
cause needs to be identified by investigation of the effect 
of the various factors individually and corrected (14,15). 
The intra-day precision also termed instrument/injection 
precision, or injection repeatability was done by the same 
analyst through repetitive injection of the same sample 
within the selected range in one day (13,14). 
Intermediate precision includes the influence of additional 
random effects such as operator, instrument, and days in 
the laboratory was calculated through inter-day precision 
method by injecting of three replicates of different 
concentrations of HMPHA (4.5, 6, 8, 10, 12.5 and 15 μg/
mL) on three consecutive days in a week (n = 9). Peak area 
was measured and % RSD was calculated (13,14). 
 
Accuracy
Recovery studies are required to check the accuracy of an 
analytical method. It ensures that the real quantification 
of target components is measured. The determination of 
this parameter was performed by adding the HMPHA 
as standard beyond the amount in the real sample 
into a blank matrix of dosage form including calcium 
phosphate, starch, and magnesium stearate and without 
P. spinosa extract. Pharmaceutical dosage form was made 
as is described in real tablets containing extract. Obtained 
tablets (n = 3) were crushed and added to a volumetric 
flask, separately. They were extracted as is mentioned in 
the sample preparation method. Then evaporated sample 
was solubilized into 1 mL of HPLC mobile phase solvent. 
For each tablet, three determinations were carried out and 
the recovery percentage was calculated in every case (14). 
 
Tablet preparation 
Formulations containing P. spinosa extract were prepared 
by wet granulation method. Five or 10 mg of standardized 
extract of P. spinosa, were mixed with lactose and/or 
tricalcium phosphate (as filler), and corn starch (as a 
disintegrating agent), then granulated using starch paste, 
and dried at 25°C. The granules were lubricated by 
magnesium stearate and compressed using a single punch 
press machine (Kilian Co, KS 43373-202, Germany). 
The resultant tablets were evaluated for their hardness, 
friability, disintegration time and weight variations. The 
drug content of tablets was determined according to the 
USP 27 (11). 
Assay of tablets 
Drug assay was carried out according to the USP 27 
requirements with some modification (11). Since the 
amounts of the active component (i.e., HMPHA) of tablets 
containing 5 and 10 mg crude extracts were less than the 
LOQ obtained by the HPLC method, six tablets of 5 mg 
and three tablets of 10 mg extract were used for drug assay. 
Tablets were crushed to a fine powder, then assayed for 
HMPHA. The powder or the extract was placed in a 100 
mL volumetric flask. Twenty milliliters of methanol was 
added to each sample and extracted overnight (24 hours), 
followed by ultra-sonication (120 minutes) in a water 
bath at 45°C. The extract so obtained was filtered and 
washed with methanol (3X). The filtrates were evaporated 
to dryness under a stream of nitrogen. The dry residue 
was resolubilized in 1 mL chloroform: methanol (9:1) and 
subjected to the HPLC assay, as explained earlier.
Statistical analysis 
Data acquisition and analysis were performed using 
Waters millennium Chromatography Software (Build 
1154, Waters Corporation, Milford, USA). The data was 
reported as mean ± SD. 
 
Results 
In selecting the best solvent for the extraction of tablets 
containing 10 μg HMPHA as standard, methanol, acetone, 
and chloroform as common solvents extracted 7.55 ± 1.56, 
1.90 ± 0.44, and 0.85 ± 0.07 μg of standard, respectively. As 
cleared methanol showed more selectivity for extraction 
of HMPHA than acetone and chloroform. The solubility 
behavior of HMPHA which is a semi polar phenolic 
compound gives us the key to the choice of the solvent. 
Theoretically, methanol with more hidelbrand parameter 
and higher hydrogen bonds with HMPHA have better 
solubility characteristics than acetone and chloroform for 
extraction of it. After selecting methanol as the extraction 
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solvent, for optimizing the extraction method, extraction 
by ultra-sonication (120 minutes) alone and maceration 
(24 hours) in combination with ultrasonic radiation (120 
minutes) were compared which retrieved 7.50 ± 1.56, and 
8.36 ± 0.25 μg standard from 10 μg tablets, respectively. 
Hence, maceration (24 hours) combined with ultra-
sonication of the tablet containing 10 μg HMPHA was 
selected as the best method for HPLC analysis. 
 
HPLC method for determination of HMPHA
The HPLC method carried out in this study was aimed to 
develop a chromatographic system, capable of separation, 
and determination of HMPHA in crude extract 
and pharmaceutical dosage forms. The preliminary 
investigations were directed toward evaluating the 
effect of various factors on the system. An initial HPLC 
separation, with a standard column Nova-Pack C18 (150 
× 3.9 mm, 4 μm), and mobile phases of water: acetonitrile 
and then phosphate buffer: acetonitrile in different ratios 
with flow rates of 1-2 mL/min provided badly overlapped 
peaks with poor separations. Then, normal phase 
chromatography was selected and affecting factors on 
resolution like mobile phase composition, temperature, 
isocratic or gradient criteria were optimized. Finally, in 
the normal phase, using a Nova-Pack Silica column (150 
× 3.9 mm) with 4 μm particle diameter, with chloroform: 
ethanol (98:2) results in rapid elution of the whole sample 
in a short time with poor separation. Then decreasing 
the solvent strength by adding the hexane to 72.5% and 
then decreasing to 22°C showed sufficient resolution with 
acceptable run time of 10 minutes. Selectivity factor and 
resolution for HMPHA with retention time of 6.9 minutes 
from its closely eluted compound, at retention time of 7.6 
minutes was obtained with α = 1.13 and Rs = 1.39. Column 
efficiency for HPMHA was 3540 theoretical plates and 
tailing factor was 1.2 using isocratic mobile phase system 
of hexane (72.5%), and chloroform: ethanol, 98:2 (27.5%) 
for 10 minutes following with an elution time of 5 minutes. 
The flow rate was 1 mL/min at 22°C and the injection 
volume for standards and samples were 20 μL (Figure 2). 
Validation 
The HPLC method for analysis of HMPHA in P. spinosa 
extract and its pharmaceutical dosage forms were validated 
through linearity, precision and accuracy tests. Using USP 
35-NF 30, the LOD and LOQ were calculated as 0.67 µg/
mL and 2.23 µg/mL for HMPHA but experimentally LOQ 
of 4.50 μg/mL was quantified with acceptable precision. 
Working range was certified with LOD of 0.67 µg/
mL, and LOQ of 4.5 µg/mL beyond values of standard 
expected in pharmaceutical dosage forms at 4.5, 6, 8, 
12.5, and 15 µg/mL. Using the millennium processing 
software, the calibration curve was determined at 291 nm 
by linear regression in the range of 4.5-15 µg/mL. The 
regression equation was y = 17346x + 826, where X is the 
concentration of HMPHA in sample (µg/mL) with the 
correlation co-factor (R2) of 0.999. However, HMPHA in 
the range of 4.5 µg/mL extended up to 250 µg/mL showed 
also linearity with correlation coefficient of 0.997 and 
equation formula of y=15041x + 47886.
The instrumental precision by intra-day results and 
intermediate precision through inter-day results 
of repetitive HMPHA quantitation in the different 
concentrations in the selected linear range, 4.5-15 μg/mL, 
and in extract as is presented in Table 1, were obtained 
with RSD < 3 which was acceptable.
In this method, accuracy was evaluated as recovery test 
after adding of 10 μg/mL HMPHA standard into a blank 
matrix of dosage form including calcium phosphate, 
starch, magnesium stearate and without P. spinosa extract, 
Figure 2. HPLC chromatogram of Pycnocycla spinosa extract containing 15 mg extract. HMPHA with retention time of 6.9 min showed 
column resolution (Rs) of 1.39 using hexane (72.5%), and chloroform: ethanol, 98:2 (27.5%) as mobile phase and flow rate of 1 mL/min 
at 22°C. Rs was calculated using equation, Rs=2(Rta-Rtb)/(Wa+Wb).
Table 1. Repeatability and intermediate precision assays of 
standards 
HMPHA
(μg/mL)
Mean ± SD
(inter-day n=9)
RSD%
(inter-day)
RSD%
(intra-day)
4.5 79576 ± 923 1.16 1.51
6 103613 ± 5660 5.46 5.28
8 139187 ± 5168 3.71 0.87
10 171231 ± 2369 1.38 1.50
12.5 220772 ± 9719 4.40 1.86
15 254538 ± 5698 2.24 2.28
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and was found to be 83.6 ± 2.31%.
Tablet preparation 
Seven different formulations containing P. spinosa extract 
were prepared by wet granulation method from 5 or 10 mg 
of standardized extract of P. spinosa. Table 2 indicates the 
amounts of various ingredients used in the formulations.
Physicochemical characteristics of tablets
The results of tablet hardness, friability, weight variations 
and disintegration time for formulation code: F4, selected 
formulation (tablet 5 mg and 10 mg) are presented in 
Table 3. All formulations had desirable physicochemical 
characteristics within UPS acceptable criteria.
Assay of tablets 
The HPLC method developed in this study was applied 
for quantification of HMPHA in tablets comprising 
5 and 10 mg plant extract (formulation F4). Figure 3 
demonstrates HPLC chromatograms of extract and tablets 
each equivalent to 30 mg extract of P. spinosa.
Discussion 
The present study is the first report of a validated 
HPLC method for standardization of P. spinosa and its 
pharmaceutical formulations. The developed method 
showed no interferences with tablet excipients and 
good resolution between HMPHA and its closely eluted 
compounds. The method showed a good linearity and 
suitability in its working range. The retention time for 
HMPHA was found to be 6.9 minutes. By the aid of the 
millennium and Excel software, the calibration curve was 
determined by linear regression in the range of 4.5 to 15 
µg/mL. The regression equation was 17346x + 826.06, 
Table 2.  Formulations of Pycnocycla spinosa tabletsa
Ingredients (mg)
Formulation code
F1 F2 F3 F4 F5 F6 F7
Extractb 5/10 5/10 5/10 5/10 5/10 5/10 5/10
Lactose 140 50 - - 95 - 95
Dicalcium Phosphate 50 140 190 95 95 - -
Starch (filler) - - - 95 - 190 95
Starch (disintegrant) 6 6 6 6 6 6 6
Magnesium Stearate 3 3 3 3 3 3 3
Starch (glue) 10 10 10 10 10 10 10
a Total weight of each tablet formulation was adjusted to 214 mg or 219 mg, based on the amount of extract used.
b The amount of dried extract used was 5 or 10 mg.
Figure 3. High performance liquid chromatography chromatograms of Pycnocycla spinosa extract and its different dosage forms. a: tablet 
of HMPHA standard (10 μg/mL); b: combined tablets of 5 mg extract of P. spinosa (6 units); c: combined tablets of 10 mg extract of P. 
spinosa (3 units). Chromatograms were carried out at 291 nm on a Nova-Pack Silica column (150 × 3.9 mm) using hexane (22.5%) as 
solvent A and chloroform: ethanol (98:2, 27.5%) as solvent B with isocratic elution at 22ºC and flow rate of 1 mL/min.
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where X is the concentration of HMPHA in the sample 
(µg/mL) with the correlation co-factor R² = 0.999 and 
the percent recovery of 83.6 ± 2.31%. Total extract of P. 
spinosa (13.78% w/w) was standardized to contain 0.041 ± 
0.002% of HMPHA which is equivalent to 0.006 ± 0.0003 
% of dried powdered plant. LOD was 0.7 µg/mL based on 
signal to noise ratio, and LOQ was 4.5 µg/mL which was 
determined experimentally. 
The limitation of this study was low sample size of 5 or 
10 mg of extract in each tablet unit containing HMPHA 
less than required for measuring the release profile of 
formulations.
Conclusion
Our data showed that the selected formulation of P. spinosa 
tablets has acceptable physicochemical features and may 
be considered as a herbal medication for treatment of 
diarrhea and IBS. 
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